Today, Corcept Therapeutics Inc. (CORT) Director Patrick G. Enright Sold 36,941 Shares

Today, Corcept Therapeutics Inc. (CORT) Director Patrick G. Enright Sold 36,941 Shares
Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 36,941 shares of the stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $9.34, for a total transaction of $345,028.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.18 on Friday. The company has a 50-day moving average of $7.78 and a 200-day moving average of $6.22. Corcept Therapeutics Inc. has a 52 week low of $3.22 and a 52 week high of $10.00. The firm has a market capitalization of $1.02 billion, a PE ratio of 235.38 and a beta of 1.64.

Several institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new position in shares of Corcept Therapeutics during the second quarter valued at about $100,000. Smith Asset Management Group LP increased its position in shares of Corcept Therapeutics by 69.2% in the second quarter. Smith Asset Management Group LP now owns 30,080 shares of the company’s stock valued at $164,000 after buying an additional 12,300 shares during the period. Falcon Point Capital LLC increased its position in shares of Corcept Therapeutics by 12.3% in the second quarter. Falcon Point Capital LLC now owns 96,575 shares of the company’s stock valued at $527,000 after buying an additional 10,569 shares during the period. Bank of New York Mellon Corp increased its position in shares of Corcept Therapeutics by 18.4% in the second quarter. Bank of New York Mellon Corp now owns 320,872 shares of the company’s stock valued at $1,752,000 after buying an additional 49,807 shares during the period. Finally, California State Teachers Retirement System increased its position in shares of Corcept Therapeutics by 19.5% in the second quarter. California State Teachers Retirement System now owns 156,638 shares of the company’s stock valued at $855,000 after buying an additional 25,574 shares during the period. 41.24% of the stock is owned by institutional investors.

A number of equities analysts have recently issued reports on CORT shares. FBR & Co reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Piper Jaffray Cos. set a $12.00 price target on shares of Corcept Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 19th. Finally, Zacks Investment Research upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Tuesday, October 18th.

About Corcept Therapeutics

Related posts

Leave a Comment